Royal Bank Of Canada Lowers Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target to $14.00

Perspective Therapeutics (NYSEAMERICAN:CATX) had its price objective decreased by investment analysts at Royal Bank Of Canada from $18.00 to $14.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Royal Bank Of Canada’s price target would suggest a potential upside of 181.86% from the stock’s previous close.

A number of other research analysts have also weighed in on the company. HC Wainwright upped their price objective on Perspective Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Friday, January 30th. Truist Financial assumed coverage on Perspective Therapeutics in a report on Monday, November 24th. They issued a “buy” rating and a $12.00 target price for the company. UBS Group restated a “buy” rating and set a $7.00 target price (down from $18.00) on shares of Perspective Therapeutics in a research report on Friday, November 21st. Piper Sandler began coverage on Perspective Therapeutics in a research report on Thursday, February 19th. They issued an “overweight” rating and a $16.00 price target for the company. Finally, Wedbush reaffirmed an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a research note on Friday, January 30th. One equities research analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $12.13.

Perspective Therapeutics Price Performance

NYSEAMERICAN:CATX traded down $0.25 during midday trading on Tuesday, reaching $4.97. The stock had a trading volume of 331,736 shares, compared to its average volume of 3,784,240. The firm has a fifty day simple moving average of $4.22 and a two-hundred day simple moving average of $3.41. Perspective Therapeutics has a 12-month low of $1.60 and a 12-month high of $6.16. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.66 and a current ratio of 8.66.

Perspective Therapeutics (NYSEAMERICAN:CATX) last announced its quarterly earnings data on Monday, March 16th. The company reported ($0.51) EPS for the quarter. Perspective Therapeutics had a negative return on equity of 40.03% and a negative net margin of 9,841.86%.The firm had revenue of $0.04 million for the quarter. On average, sell-side analysts predict that Perspective Therapeutics will post -0.88 earnings per share for the current year.

Institutional Investors Weigh In On Perspective Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. increased its position in Perspective Therapeutics by 5.0% during the third quarter. Vanguard Group Inc. now owns 3,437,865 shares of the company’s stock worth $11,792,000 after buying an additional 163,532 shares in the last quarter. Avidity Partners Management LP lifted its position in shares of Perspective Therapeutics by 7.2% in the fourth quarter. Avidity Partners Management LP now owns 3,210,733 shares of the company’s stock valued at $8,830,000 after acquiring an additional 216,700 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Perspective Therapeutics by 15.8% in the second quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company’s stock valued at $4,758,000 after acquiring an additional 188,887 shares in the last quarter. Opaleye Management Inc. acquired a new stake in shares of Perspective Therapeutics during the fourth quarter valued at $3,257,000. Finally, State Street Corp increased its position in Perspective Therapeutics by 3.3% during the 4th quarter. State Street Corp now owns 1,141,247 shares of the company’s stock worth $3,138,000 after purchasing an additional 36,543 shares in the last quarter. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.